Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 2, pp 249–257 | Cite as

A phase I trial of flavopiridol in relapsed multiple myeloma

  • Craig C. Hofmeister
  • Ming Poi
  • Mindy A. Bowers
  • Weiqiang Zhao
  • Mitch A. Phelps
  • Don M. Benson
  • Eric H. Kraut
  • Sherif Farag
  • Yvonne A. Efebera
  • Jennifer Sexton
  • Thomas S. Lin
  • Michael Grever
  • John C. Byrd
Original Article



Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile.


Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flavopiridol was administered as a bolus and then continuous infusion weekly for 4 weeks in a 6-week cycle.


Fifteen patients were treated at three dose levels (30 mg/m2 bolus, 30 mg/m2 CIV to 50 mg/m2 bolus, and 50 mg/m2 CIV). Cytopenias were significant, and elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were noted but were transient. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) did not lead to hospital admission. There were no confirmed partial responses although one patient with t(4;14) had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response.


Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma ( identifier NCT00112723).


Multiple myeloma Flavopiridol Cyclin-dependent kinase inhibitor Pharmacokinetics Phase 1 clinical trial 



Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA076576 (PI Michael Grever). CCH was a Paul Calabresi scholar on K12CA133250 from the National Cancer Institute (PI John Byrd). The content is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute or the National Institutes of Health.

Conflict of interest

None of the authors have a relevant conflict of interest to report.


  1. 1.
    Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303PubMedCrossRefGoogle Scholar
  2. 2.
    Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95:1098–1105PubMedCrossRefGoogle Scholar
  3. 3.
    Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404PubMedCrossRefGoogle Scholar
  4. 4.
    Chao SH, Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793–31799PubMedCrossRefGoogle Scholar
  5. 5.
    Classon M, Dyson N (2001) p107 and p130: versatile proteins with interesting pockets. Exp Cell Res 264:135–147PubMedCrossRefGoogle Scholar
  6. 6.
    Cobrinik D (2005) Pocket proteins and cell cycle control. Oncogene 24:2796–2809PubMedCrossRefGoogle Scholar
  7. 7.
    Dai Y, Hamm TE, Dent P, Grant S (2006) Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle 5:437–446PubMedCrossRefGoogle Scholar
  8. 8.
    De Azevedo WF Jr, Canduri F, da Silveira NJ (2002) Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 293:566–571PubMedCrossRefGoogle Scholar
  9. 9.
    Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC (2006) Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 91:390–393PubMedGoogle Scholar
  10. 10.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRefGoogle Scholar
  11. 11.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRefGoogle Scholar
  12. 12.
    Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527–3538PubMedGoogle Scholar
  13. 13.
    Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S (2011) Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 17:3388–3397PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111:3190–3199PubMedCrossRefGoogle Scholar
  15. 15.
    Kramer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R (2002) Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 16:1844–1851PubMedCrossRefGoogle Scholar
  16. 16.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520PubMedCrossRefGoogle Scholar
  17. 17.
    Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jager U, Chopra R (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154:325–336PubMedCrossRefGoogle Scholar
  18. 18.
    Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SEM, Smith LL, Yeh Y-Y, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC (2012) ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 120:1262–1273Google Scholar
  19. 19.
    Massague J (2004) G1 cell-cycle control and cancer. Nature 432:298–306PubMedCrossRefGoogle Scholar
  20. 20.
    McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS (2011) Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 152:420–432PubMedCrossRefGoogle Scholar
  21. 21.
    Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637–2645PubMedCrossRefGoogle Scholar
  22. 22.
    Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT (2008) Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci 868:110–115PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N (2010) AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29:2325–2336PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Semenov I, Akyuz C, Roginskaya V, Chauhan D, Corey SJ (2002) Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 26:271–280PubMedCrossRefGoogle Scholar
  25. 25.
    Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM (2008) IRF4 addiction in multiple myeloma. Nature 454:226–231PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677PubMedCrossRefGoogle Scholar
  27. 27.
    Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 97:228–233PubMedCrossRefGoogle Scholar
  28. 28.
    Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279:4750–4759PubMedCrossRefGoogle Scholar
  29. 29.
    Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM (2004) Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10:5038–5047PubMedCrossRefGoogle Scholar
  30. 30.
    Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771–4779PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Craig C. Hofmeister
    • 1
  • Ming Poi
    • 2
  • Mindy A. Bowers
    • 3
  • Weiqiang Zhao
    • 4
  • Mitch A. Phelps
    • 5
  • Don M. Benson
    • 1
  • Eric H. Kraut
    • 1
  • Sherif Farag
    • 6
  • Yvonne A. Efebera
    • 1
  • Jennifer Sexton
    • 3
  • Thomas S. Lin
    • 7
  • Michael Grever
    • 1
  • John C. Byrd
    • 1
  1. 1.Division of HematologyThe Ohio State UniversityColumbusUSA
  2. 2.Department of PharmacyThe Ohio State University Comprehensive Cancer CenterColumbusUSA
  3. 3.The Ohio State University Comprehensive Cancer CenterColumbusUSA
  4. 4.Department of Pathology, College of MedicineThe Ohio State UniversityColumbusUSA
  5. 5.College of PharmacyThe Ohio State UniversityColumbusUSA
  6. 6.College of MedicineIndiana University School of MedicineIndianapolisUSA
  7. 7.Oncology Research and DevelopmentGlaxoSmithKlinePhiladelphiaUSA

Personalised recommendations